Smith & Nephew expecting a Q4 underlying revenue decline of approximately -7%

Smith & Nephew plc

Smith & Nephew plc (LON:SN), the global medical technology business, has announced that it expects a fourth quarter underlying1 revenue decline of approximately -7%. Sales were impacted by increased rates of COVID-19 infection from mid-October onwards, particularly in the US and Europe where more procedures were postponed following the reintroduction of restrictions.

As in previous months, the impact was most pronounced on our Orthopaedic Reconstruction, Sports Medicine and ENT businesses, driven by lower levels of elective surgery. Our Advanced Wound Management and Trauma businesses remained more resilient.

Full year underlying revenue is expected to have declined approximately
-12%. As previously stated, the trading profit margin will be substantially down year-on-year, with negative operating leverage due to lower volumes partially offset by cost control measures.

Throughout 2020 we continued to serve customers, develop and launch new products and make acquisitions, whilst prioritising the health and wellbeing of employees.

Further detail of the trading performance, including franchise and regional sales performance, trading profit margin, and a review of our strategic progress in 2020, will be provided with Smith & Nephew’s fourth quarter and full year results, scheduled for 18 February 2021.

Share on:
Find more news, interviews, share price & company profile here for:

    Fidelity Asian Values gains on significant China exposure (LON: FAS)

    The Trust’s NAV rose by 1.8% for the 12 months to 31 May 2025, outperforming its reference index, which declined 0.6%. Strong stock selection, particularly in China, materials, and technology, contributed to gains, while overweight positions in Indonesian small caps detracted.

    Emerging markets fund FEML rises on trade and AI optimism

    Fidelity Emerging Markets gained in May, supported by easing trade tensions and investor enthusiasm for AI. The portfolio outperformed the index, with strong stock picking in materials and consumer discretionary sectors.

    Pharos Energy CEO and CFO increase shareholdings

    Pharos Energy plc announced that CEO Katherine Roe and CFO Sue Rivett purchased shares on 27 June 2025 at £0.21266 per share under existing trading plans.

    TEAM Plc grows revenue and client assets ahead of UCITS fund launch

    TEAM plc reported interim revenue growth to £5.8m and a rise in client assets to £1.112bn for HY25. The Group reduced annual operating costs by £668k and expanded its international advisory network to 59 advisers.

    Aptamer advances liver fibrosis therapy with targeted gene delivery

    Aptamer Group has identified a novel target using its Optimer® platform to deliver gene therapy directly to liver scarring cells.

    SAE Renewables advances battery projects and marks 10 years on AIM

    SAE Renewables reported steady progress in 2024, securing full ownership of its 240MWh AW1 battery project and submitting plans for a 1,200MWh system in Scotland. Revenues reached £14.4m, with EBITDA at £7.9m.

      Search

      Search